Assenagon Asset Management
CRNX icon

Assenagon Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Assenagon Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,338
Closed -$514K – 1176
2025
Q3 		$514K Buy
+12,338
New +$394K ﹤0.01% 1048

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Assenagon Asset Management's CRNX Position: Q4 2025 in Review

Assenagon Asset Management sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 12,338 shares — an estimated $514K sold.

Assenagon Asset Management first reported a position in CRNX in Q3 2025 and held it in 1 quarter. The position peaked at $514K in Q3 2025. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

  • Assenagon Asset Management reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Assenagon Asset Management sold 12,338 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $514K.
  • Assenagon Asset Management first reported a position in Crinetics Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Assenagon Asset Management's Crinetics Pharmaceuticals position peaked at $514K in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Assenagon Asset Management's 13F filing for Q4 2025, filed 9 Jan 2026.